The Oncology Institute Q4 2023 GAAP EPS $(0.21) Misses $(0.11) Estimate, Sales $85.788M Beat $82.042M Estimate
Portfolio Pulse from Benzinga Newsdesk
The Oncology Institute (NASDAQ:TOI) reported Q4 2023 earnings with a GAAP EPS of $(0.21), missing the $(0.11) estimate by 90.91%, but sales of $85.788M exceeded the $82.042M estimate by 4.57%, marking a 20.11% increase from the previous year.
March 27, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The Oncology Institute reported a Q4 2023 GAAP EPS of $(0.21), missing estimates, but sales of $85.788M exceeded expectations and grew 20.11% YOY.
While the EPS miss could negatively impact investor sentiment, the significant sales beat and year-over-year growth may offset this, leading to a neutral short-term price direction. The mixed results present both positive and negative signals to investors, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100